As recommended by the NCCN guidelines, treatment can be continued with a regimen of gemcitabine +albumin-bound paclitaxel for patients with patent biliary tracts and good nutritional status (5) (NCCN Guidelines, Pancreatic Adenocarcinoma, Version 1, 2022). This evidence concerns the gene ALB and pancreatic adenocarcinoma.